Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy

Date

21 Oct 2023

Session

Poster session 13

Topics

Translational Research;  Immunotherapy

Tumour Site

Melanoma

Presenters

Domenico Mallardo

Citation

Annals of Oncology (2023) 34 (suppl_2): S651-S700. 10.1016/S0923-7534(23)01941-5

Authors

D. Mallardo1, M. Fordellone2, A. White3, M. Ottaviano1, F. Sparano1, M. Bailey4, B.A. Facchini1, S. Ong5, P. maiolino6, C. Caracò17, S.E. Church8, E. Cavalcanti9, S. Warren4, A. Budillon10, A. Cesano4, E. Simeone1, P. Chiodini2, P.A. Ascierto1

Author affiliations

  • 1 Melanoma, Cancer Immunotherapy And Development Therapeutics Department, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 2 Medical Statistics Unit, Universita degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 3 Research And Development, NanoString Technologies, Seattle/US
  • 4 Research And Development, NanoString Technologies, Inc., 98109 - Seattle/US
  • 5 Research And Development, NanoString Technologies, 98109 - Seattle/US
  • 6 Hospital Pharmacy, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 7 Division Of Surgery Of Melanoma And Skin Cancer, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 8 R&d, NanoString Technologies, 98109 - Seattle/US
  • 9 Division Of Laboratory Medicine, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 10 Translational Research, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1163P

Background

The immune checkpoint inhibitors (ICIs) revolutionized cancer therapeutic landscape and substantially improved the survival of patients (pts) with advanced malignancies. Several predictive biomarkers are under evaluation, in order to identify patients who can benefit from ICI. Recently, elevated NLR, calculated from absolute neutrophil count and white cell count, were found to be independent predictors of reduced survival and increased risk of progression in melanoma patients receiving ICI. The purpose of this study is to retrospectively investigate relationship of NLR with inflammation-immune mediators.

Methods

Gene profiling analysis was performed from 78 basal PBMCs of metastatic melanoma pts treated in first line with anti-PD1 using NanoString IO360 panel. Patient’s characteristics are listed in table. To identify the best genes signature the Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) was applied.

Results

Overall, 78 patients were included in the analysis. Pts with high NLR at baseline (ratio >5.57) had a poorer PFS (HR=7.27, 95% CI = 3.5-14.8; p < 0.0001) and OS (HR=3.98; 95% CI = 2.0-7.9) than the pts with low NLR. Brain metastases were present in a higher proportion of pts with high NLR compared to those with low NLR (p=0.01). In the trascriptomic analysis, NLR was associated with SH2D1A, CD3, ZAP70, CD45RA genes, while a high NLR with CCNA1, LDHA, IL18R1, CD39, PTEN, MYD88 and MMP9 genes (ROC curve, AUC=0.97, p<0001). The signatures are also associated to response. In addition, CD39 expression is higher in NLR high and is associate with increase of N2 neutrophils. NLR increase on treatment is also associated to worse outcome and a specific genetic signature. Table: 1163P

Patient characteristics N = 78
Median age 61 (range 27-91)
Gender: female/male, n (%) 41 (53)/37 (47)
Melanoma AJCC VII Stage
Stage IV, n (%) 74 (94)
Stage IIIC 4 (5)
Stage IIIB 1 (1)
CNS metastases at baseline, n (%) 18 (23)
BRAF Status
Wilde type, n (%) 59 (76)
Mutation, n (%) 16 (21)
NA, n (%) 3 (3)
Response rate at 1st assessment
Complete response, n (%) 9 (11)
Partial response, n (%) 16 (21)
Stable disease, n (%) 17 (22)
Progression disease, n (%) 36 (46)
ORR, n (%) 39 (50)
DCR, n (%) 25 (32)
LDH
High 26 (33)
Normal 34 (44)
NA 18 (23)

Conclusions

NLR high is related with immunosuppressive, inflammatory and tumor related genes; in particular with N2 neutrophils associate to adenosine pathway activation. This could explain the prognostic role of NLR. Further investigations are needed to get additional information.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Paolo Antonio Ascierto.

Funding

Italian Ministry of Health (IT-MOH).

Disclosure

A. White, M. Bailey, S. Ong, S.E. Church, S. Warren, A. Cesano: Financial Interests, Personal, Stocks or ownership: NanoString. P.A. Ascierto: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.